Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kaken Pharmaceutical is a Japanese specialty pharmaceutical company focused on dermatology, with flagship products including Beselna (imiquimod) for actinic keratosis and Duobrii (halobetasol/tazarotene) for psoriasis. The company operates primarily in Japan's domestic pharmaceutical market with selective international partnerships, competing through specialized dermatological formulations rather than broad therapeutic portfolios. Stock performance is driven by domestic prescription volumes, regulatory approvals for line extensions, and reimbursement pricing dynamics under Japan's National Health Insurance system.
Kaken generates revenue through Japan's National Health Insurance reimbursement system for prescription products, capturing premium pricing for differentiated topical formulations with improved efficacy or tolerability profiles. The company's competitive advantage lies in specialized drug delivery technologies for dermatological applications and established relationships with Japanese dermatologists. Gross margins of 62% reflect formulation complexity and limited generic competition for newer products, though biennial NHI price revisions create downward pricing pressure. Operating leverage is moderate as the company maintains its own sales force targeting dermatology specialists.
Quarterly prescription volume trends for key products (Beselna, Duobrii) tracked through Japanese pharmacy dispensing data
Biennial NHI drug price revision outcomes (April of even-numbered years) - typically 5-10% cuts for established products
New product approvals from PMDA (Pharmaceuticals and Medical Devices Agency) for line extensions or reformulations
Generic competition timelines for off-patent products as exclusivity periods expire
Yen exchange rate movements affecting international royalty income and imported raw material costs
Japan's biennial NHI drug price revisions create systematic downward pricing pressure, with established products facing 5-10% cuts every two years, requiring continuous new product launches to offset revenue erosion
Aging Japanese population creates long-term market opportunity but also intensifies government cost containment efforts through accelerated generic substitution policies and stricter reimbursement criteria
Limited geographic diversification concentrates revenue in Japan's mature pharmaceutical market with slower growth than emerging markets
Generic competition from domestic manufacturers (Towa, Nichi-Iko) upon patent expiry erodes pricing power for off-patent products within 12-18 months
Global dermatology specialists (LEO Pharma, Galderma) entering Japanese market through partnerships with larger distributors could pressure market share
Biosimilar and biologic competition for inflammatory dermatological conditions (IL-17, IL-23 inhibitors) may shift treatment paradigms away from topical therapies
Negative ROE of -2.6% and ROA of -2.4% despite strong operating margins suggests recent equity issuance, acquisition write-downs, or pension adjustments that warrant investigation
Extremely high FCF yield of 2,503% appears anomalous and may indicate data quality issues, one-time asset sales, or currency conversion errors requiring verification
Current ratio of 4.09 indicates excess liquidity that could signal inefficient capital allocation or preparation for large acquisition
low - Prescription pharmaceutical demand is largely non-discretionary and insulated from economic cycles. Dermatological conditions requiring treatment persist regardless of GDP growth. However, OTC skincare products (15-20% of revenue) show modest sensitivity to consumer discretionary spending. Japan's aging demographics provide structural tailwind for chronic dermatological conditions.
Low direct sensitivity given minimal debt (0.03 D/E ratio) and strong cash position (4.09 current ratio). Rising rates in Japan could marginally impact valuation multiples for healthcare stocks, but operational impact is negligible. The company's negative ROE of -2.6% despite strong margins suggests recent equity dilution or one-time charges rather than interest expense pressure.
Minimal - The company operates with negligible leverage and does not depend on credit markets for operations. Customer credit risk is minimal as revenues flow through Japan's government-backed National Health Insurance system. Supplier financing is not a material factor given strong working capital position.
value - The 2.1x P/S ratio and 1.1x P/B valuation suggest value orientation despite 30.5% revenue growth. Negative ROE creates contrarian opportunity for investors betting on turnaround. The combination of strong cash generation ($25.4B FCF) and low valuation multiples attracts value investors focused on cash flow yield rather than growth multiples. Limited analyst coverage on Japanese small-cap pharma creates potential for undiscovered value.
moderate - As a Japanese small-cap healthcare stock with limited liquidity, expect higher volatility than large-cap pharma. The 11.6% three-month return versus -4.7% six-month return indicates episodic volatility around product news or earnings. Yen volatility adds currency risk for international investors. Healthcare sector defensiveness partially offsets small-cap volatility.